阿司匹林在冠心病患者中C反应蛋白及血小板的影响

目的研究阿司匹林(ASP)对冠心病(CHD)患者血浆C-反应蛋白(CRP)及血小板(Platelet)功能的影响,了解它们与CHD的关系。方法将90例CHD病人,随机分为两组:I组口服ASP 50 mg/d,II组ASP 150 mg/d,早餐后顿服;8周后检验两组患者的血浆CRP浓度、血小板膜表面α颗粒膜蛋白(GMP-140)和血小板聚集率的变化。结果与治疗前比较,除I组CRP浓度变化差异无显著性外,其余各项指标均有显著性差异(P>0.05),组间比较差异有显著性(P>0.05)。结论使用ASP 150 mg/d能直接降低血浆CRP浓度、GMP-140水平和抑制血小板活化和聚集,能有效地防止冠状血管的进一步损害。

The effect of aspirin on CRP and platelet function in patients with CHD

Objective To investigate the effect of aspirin(ASP) on C-reactive protein(CRP) and platelet function in patients with CHD and their relationship with CHD.Methods 90 patients with CHD were randomized to either ASP 50mg/d p.o.after breakfast(group I) or to ASP 150 mg/d p.o.after breakfast(Group II),Eight weeks later,CRP,Platelet GMP-140 and platelet aggregation were tested.Results As compared with baseline values,all the indices changed significantly after treatment(P<0.05),with the exception of CRP concentrations in group I patients.There were statistically significant differences between the two groups(P<0.05).Conclusion ASP 150 mg/d can significantly reduce CRP and GMP-140 levels,inhibit platelet activation and aggregation,effectively prevent further damage to the coronary arteries.